Certara - About the company
Certara is a public company based in Princeton (United States), founded in 2008. It operates as a Provider of a platform for in silico drug discovery and consulting services. Certara has raised an undisclosed amount in funding. The company has 178 active competitors, including 43 funded and 19 that have exited. Its top competitors include companies like Cartography Biosciences, TOLREMO therapeutics and Pharmacelera.
Company Details
Provider of a platform for in silico drug discovery and consulting services. It has software solutions for molecular modeling and simulation, pharmacokinetic and pharmacodynamic simulation, clinical trial simulators, and scientific informatics. The company provides drug development consulting and medical writing services.
- Website
- certara.com
- Registered Address
- Princeton, New Jersey
Key Metrics
Founded Year
2008
Location
Princeton, United States
Stage
Public
Latest Funding Round
Ranked
1st among 178 active competitors
Annual Revenue
$100M - $500M as on Dec 31, 2025
Employee Count
1,512 as on May 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Certara
Certara is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CERTARA SOFTWARE INDIA PRIVATE LIMITED CIN: U72900KA2012PTC064356 , India, Active | Jun 12, 2012 | ₹10 - ₹50 Cr (As on Mar 31, 2025) | - | |
CERTARA, INC. CIN: 1827090 , United States, Active | Jun 26, 2017 | $100M - $500M (As on Dec 31, 2025) | 1338 (As on Dec 31, 2023) | - |
CERTARA UK LIMITED CIN: 4217235 , United Kingdom, Active | May 14, 2001 | £10M - £50M (As on Dec 31, 2022) | 230 (As on Dec 31, 2022) | |
CERTARA USA, INC. CIN: 510625438 , United States, Active | Dec 26, 999 | - | 568 (As on Dec 31, 2024) | - |
Certara's IPO details
Certara got listed on Dec 11, 2020.
Click here to take a look at Certara's IPO in detail
Sign up to download Certara's company profile
Certara's funding and investors
Certara has raised funding over 6 rounds. Its first funding round was on Dec 19, 2013. Its latest funding round was a Grant (prize money) round on Sep 23, 2021 for $*****. 1 investor participated in its latest round. Certara has 5 institutional investors.
Here is the list of recent funding rounds of Certara:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 23, 2021 | 8921767 | Grant (prize money) | 6560073 | 6926021 | 1292960 | 4831141 |
Jul 27, 2021 | 3774715 | Post IPO | 8669229 | 7827518 | 5529236 | |
Jun 01, 2021 | 5047147 | Grant (prize money) | 3424780 | 5325451 | 4846066 |
View details of Certara's funding rounds and investors
Certara's founders and board of directors
Founder? Claim ProfileCertara's employee count trend
Certara has 1,512 employees as of May 26. Here is Certara's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Certara's Competitors and alternates
Top competitors of Certara include Cartography Biosciences, TOLREMO therapeutics and Pharmacelera. Here is the list of Top 10 competitors of Certara, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Certara 2008, Princeton (United States), Public | Provider of a platform for in silico drug discovery and consulting services | - | 65/100 | |
2nd | Cartography Biosciences 2020, Foster City (United States), Series B | Provider of a platform to discover immunotherapeutics | $124M | 62/100 | |
3rd | TOLREMO therapeutics 2017, Zurich (Switzerland), Series A | Developing anti-cancer small molecules targeting novel drug resistance pathways | $55.8M | 60/100 | |
4th | Pharmacelera 2015, Barcelona (Spain), Series A | Hardware and software solutions for computer-aided drug design | $7.1M | 59/100 | |
5th | Oxford Drug Design 2001, Oxford (United Kingdom), Series A | Provider of computer-aided design of antibiotics for MDR infections | $12.4M | 59/100 | |
6th | Inpharmatica 1998, London (United Kingdom), Acquired | Developer of predictive informatics based platform for drug discovery | $75M | 58/100 | |
7th | HotSpot Therapeutics 2017, Boston (United States), Series C | Developer of a platform for protein function analysis | $210M | 57/100 | |
8th | Genialis 2015, Boston (United States), Series A | Developer of end-to-end bioinformatics software solutions | $16M | 56/100 | |
9th | AI-based precision medicine supporting tool for drug discovery | - | 55/100 | ||
10th | Probius 2016, Fremont (United States), Seed | Digital biochemical analysis tool for healthcare researchers | $2.43M | 55/100 |
Looking for more details on Certara's competitors? Click here to see the top ones
Certara's Investments and acquisitions
Certara has not made any investments yet. Certara has made 10 acquisitions.Here is the list of latest three $acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jul 09, 2024 | Acquisition | 1998 | Budapest (Hungary) | |
Dec 13, 2023 | Acquisition | 2013 | Cambridge (United States) | |
Jan 04, 2023 | Acquisition | 2016 | Newburyport (United States) |
See all acquisitions by Certara
Reports related to Certara
Here is the latest report on Certara's geography:
News related to Certara
Media has covered Certara for a total of 26 events in the last 1 year, 13 of them have been about company updates and 3 about partnerships.
•
•
•
Certara, Inc. Shareholders Encouraged to Contact Johnson Fistel Regarding Potential Loss RecoveryGlobeNewswire•May 12, 2026•Johnson Fistel, Certara, Bragar Eagel & Squire, Schall Law Firm and 1 other
•
Certara Reports First Quarter 2026 Financial Results and Updates 2026 GuidanceGlobeNewswire•May 11, 2026•Certara
•
Altasciences and Certara announce a strategic partnership to accelerate early drug developmentBusiness Wire•May 08, 2026•Altasciences, Certara
•
Certara Enters Agreement to Sell Regulatory and Medical Writing Business to VeristatGlobeNewswire•Apr 22, 2026•Veristat, Certara
•
Dixon Mitchell Investment Counsel Inc. Purchases Shares of 866,380 Certara, Inc.MarketBeat•Mar 10, 2026•Dixon Mitchell, Certara
•
•
•
Are you a Founder ?
FAQs about Certara
Explore our recently published companies
- Fabric - San Francisco based, 2022 founded, Funding Raised company
- Ambit Equity - Munich based, 2021 founded, Unfunded company
- A Malgam Technologies - Quebec City based, 2016 founded, Funding Raised company
- Billbo - Visakhapatnam based, Unfunded company
- Sooq Al Thahab - Manama based, 2022 founded, Funding Raised company
- Second Ocean - South Korea based, 2025 founded, Funding Raised company